30 Ağustos 2021 Dergi makalesi Açık Erişim

Ebru; Salih; Tuğba; Ömer Faruk; Öznur Özge; Tuğçe; Mesut; Muhsin

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/227979</identifier>
  <creators>
    <creator>
      <creatorName>Ebru</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-0395-9845</nameIdentifier>
      <affiliation>ÖZKAN OKTAY</affiliation>
    </creator>
    <creator>
      <creatorName>Salih</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0003-3838-5228</nameIdentifier>
      <affiliation>TUNCAY</affiliation>
    </creator>
    <creator>
      <creatorName>Tuğba</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-5885-0193</nameIdentifier>
      <affiliation>KAMAN</affiliation>
    </creator>
    <creator>
      <creatorName>Ömer Faruk</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-7803-3249</nameIdentifier>
      <affiliation>KARASAKAL</affiliation>
    </creator>
    <creator>
      <creatorName>Öznur Özge</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-8992-0556</nameIdentifier>
      <affiliation>ÖZCAN</affiliation>
    </creator>
    <creator>
      <creatorName>Tuğçe</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-4663-897X</nameIdentifier>
      <affiliation>SOYLAMIŞ</affiliation>
    </creator>
    <creator>
      <creatorName>Mesut</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-8971-678X</nameIdentifier>
      <affiliation>KARAHAN</affiliation>
    </creator>
    <creator>
      <creatorName>Muhsin</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-6651-718X</nameIdentifier>
      <affiliation>KONUK</affiliation>
    </creator>
  </creators>
  <titles>
    <title>An Update Comprehensive Review On The Status Of Covid-19: Vaccines, Drugs, Variants And Neurological Symptoms</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2021</publicationYear>
  <subjects>
    <subject>COVID-19</subject>
    <subject>variants</subject>
    <subject>neurological symptoms</subject>
    <subject>drugs</subject>
    <subject>vaccines</subject>
    <subject>neutralizing antibodies</subject>
    <subject>SARS-CoV-2</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2021-08-30</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/227979</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.3906/biy-2106-23</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by-sa">Creative Commons Attribution Share-Alike</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory&amp;nbsp;syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory&amp;nbsp;tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been&amp;nbsp;developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants&amp;nbsp;of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B&amp;nbsp;1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological&amp;nbsp;manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent&amp;nbsp;plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory&amp;nbsp;tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines&amp;nbsp;that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its&amp;nbsp;correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs,&amp;nbsp;and action against emerging viral mutant variants is needed.&lt;/p&gt;</description>
  </descriptions>
</resource>